|drug623||COVID-19 convalescent plasma Wiki||1.00|
There is one clinical trial.
The purpose of this study is to identify early signals of efficacy or harm associated with convalescent plasma therapy in a population of Veteran inpatients with coronavirus disease 2019 (COVID-19).
Description: Death at any time after admission recorded in the electronic health record. Specific estimates of risk of death will be produced for 7 days, 14 days, 21 days and 28 days, and total deaths.Measure: All-cause mortality Time: up to 28 days
Description: Number of days from index date to first intubation in non-mechanically ventilated patientsMeasure: Time to first intubation Time: 28 days
Description: Number of days from index date to hospital dischargeMeasure: Time to hospital discharge Time: 28 days
Description: Number of days from index date to death from any causeMeasure: Time to all-cause mortality Time: 28 days
Description: Long-term outcomes will include death at one year following the index date.Measure: All-cause mortality Time: 1 year
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports